Sign in
Stories
Biopharmaceutical Companies' Q2 Results
Share
AB Ignitis grup to Present 6M 2023 Resul...
AB Ignitis grup to Present 6M 2023 Resul...
Amarin Q1 2024 Financial Update
Overview
API
Zai Lab and Arbutus Biopharma are set to release their second-quarter financial results, with Zai Lab anticipating significant revenue growth and corporate profitability by 2025. Zai Lab's portfolio includes late-stage assets and over 15 commercial-stage products by 2028. Arbutus Biopharma is concentrating on developing therapeutics for viral diseases and is currently working on an RNAi therapeutic and an oral PD-L1 inhibitor for HBV. Both companies are set to provide updates on their financial performance and upcoming projects.
Ask a question
How do the financial results of Zai Lab and Arbutus Biopharma reflect the broader trends in the biopharmaceutical market?
How might Zai Lab's projected revenue growth and corporate profitability impact the global biopharmaceutical industry?
What challenges and opportunities do Arbutus Biopharma and Zai Lab face in their respective therapeutic areas?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
May 2023
Jun 2023
Jul 2023
Coverage